159 research outputs found
Annual Meeting of the International Society of Cancer Metabolism (ISCaM): Cancer Metabolism
Tumors are metabolic entities wherein cancer cells adapt their metabolism to their
oncogenic agenda and microenvironmental influences. Metabolically different cancer
cell subpopulations collaborate to optimize nutrient delivery with respect to immediate
bioenergetic and biosynthetic needs. They can also metabolically exploit host cells. These
metabolic networks are directly linked with cancer progression, treatment, resistance,
and relapse. Conversely, metabolic alterations in cancer are exploited for anticancer
therapy, imaging, and stratification for personalized treatments. These topics were
addressed at the 4th annual meeting of the International Society of Cancer Metabolism
(ISCaM) in Bertinoro, Italy, on 19–21 October 201
ACYLATED AND UNACYLATED GHRELIN IMPAIR SKELETAL MUSCLE ATROPHY IN MICE.
Cachexia is a wasting syndrome associated with cancer, AIDS, and multiple sclerosis, and several
other disease states. It is characterized by weight loss, fatigue, loss of appetite and skeletal muscle
atrophy and is associated with poor patient prognosis, making it an important treatment target.
Ghrelin is a peptide hormone that stimulates growth hormone (GH) release and positive energy
balance through binding to the receptor GHSR-1a. Only acylated ghrelin (AG), but not the
unacylated form (UnAG), can bind GHSR-1a; however, UnAG and AG share several GHSR-1aindependent
biological activities. Here we investigated whether UnAG and AG could protect
against skeletal muscle atrophy in a GHSR-1a-independent manner. We found that both AG and
UnAG inhibited dexamethasone-induced skeletal muscle atrophy and atrogene expression through
PI3K\u3b2-, mTORC2-, and p38-mediated pathways in myotubes. Up-regulation of circulating UnAG
in mice impaired skeletal muscle atrophy induced by either fasting or denervation without
stimulating muscle hypertrophy and GHSR-1a-mediated activation of the GH/IGF-1 axis. In Ghsrdeficient
mice, both AG and UnAG induced phosphorylation of Akt in skeletal muscle and
impaired fasting-induced atrophy. These results demonstrate that AG and UnAG act on a common,
unidentified receptor to block skeletal muscle atrophy in a GH-independent manner
Unacylated ghrelin promotes adipogenesis in rodent bone marrow via ghrelin O-acyl transferase and GHS-R1a activity: evidence for target cell-induced acylation
Despite being unable to activate the cognate ghrelin receptor (GHS-R), unacylated ghrelin (UAG) possesses a unique activity spectrum that includes promoting bone marrow adipogenesis. Since a receptor mediating this action has not been identified, we re-appraised the potential interaction of UAG with GHS-R in the regulation of bone marrow adiposity. Surprisingly, the adipogenic effects of intra-bone marrow (ibm)-infused acylated ghrelin (AG) and UAG were abolished in male GHS-R-null mice. Gas chromatography showed that isolated tibial marrow adipocytes contain the medium-chain fatty acids utilised in the acylation of UAG, including octanoic acid. Additionally, immunohistochemistry and immunogold electron microscopy revealed that tibial marrow adipocytes show prominent expression of the UAG-activating enzyme ghrelin O-acyl transferase (GOAT), which is located in the membranes of lipid trafficking vesicles and in the plasma membrane. Finally, the adipogenic effect of ibm-infused UAG was completely abolished in GOAT-KO mice. Thus, the adipogenic action of exogenous UAG in tibial marrow is dependent upon acylation by GOAT and activation of GHS-R. This suggests that UAG is subject to target cell-mediated activation – a novel mechanism for manipulating hormone activity
Role of monocarboxylate transporters in human cancers : state of the art
Monocarboxylate transporters (MCTs) belong to the SLC16 gene family, presently composed by 14 members. MCT1-MCT4 are proton symporters, which mediate the transmembrane transport of pyruvate, lactate and ketone bodies. The role of MCTs in cell homeostasis has been characterized in detail in normal tissues, however, their role in cancer is still far from understood. Most solid tumors are known to rely on glycolysis for energy production and this activity leads to production of important amounts of lactate, which are exported into the extracellular milieu, contributing to the acidic microenvironment. In this context, MCTs will play a dual role in the maintenance of the hyper-glycolytic acidresistant phenotype of cancer, allowing the maintenance of the high glycolytic rates by performing lactate efflux, and pH regulation by the co-transport of protons. Thus, they constitute attractive targets for cancer therapy, which have been little explored. Here we review the literature on the role of MCTs in solid tumors in different locations, such as colon, central nervous system, breast, lung, gynecologic tract, prostate, stomach, however, there are many conflicting results and in most cases there are no functional studies showing the dependence of the tumors on MCT expression and activity. Additional studies on MCT expression in other tumor types, confirmation of the results already published as well as additional functional studies are needed to deeply understand the role of MCTs in cancer maintenance and aggressiveness
Cancer stem cell metabolism
Cancer is now viewed as a stem cell disease. There is still no consensus on the metabolic characteristics of cancer stem cells, with several studies indicating that they are mainly glycolytic and others pointing instead to mitochondrial metabolism as their principal source of energy. Cancer stem cells also seem to adapt their metabolism to microenvironmental changes by conveniently shifting energy production from one pathway to another, or by acquiring intermediate metabolic phenotypes. Determining the role of cancer stem cell metabolism in carcinogenesis has become a major focus in cancer research, and substantial efforts are conducted towards discovering clinical targets
- …